Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294;

Recommend :
React to this article
Latest news on GILEAD SCIENCES, INC.
1h ago GILEAD SCIENCES : Announces Generic Licensing Agreements to Increase Access to H..
1d ago STRIDES ARCOLAB : partners with Gilead Sciences Inc, to bring ; Hepatitis C cure..
2d ago S&P 500 MOVERS : Gild, tap
2d agoDJU.S. HOT STOCKS : Hot Stocks to Watch
2d ago GILEAD SCIENCES : to license generic version of Sovaldi
2d ago GILEAD SCIENCES : Announces Generic Licensing Agreements to Increase Access to H..
6d ago GILEAD SCIENCES : Reports Results of Ambrisentan and Tadalafil Study
7d ago GILEAD SCIENCES : to Present at Two Upcoming Investor Conferences in September
09/08DJGSK Announces Results of Late-Stage PAH Trial With Gilead
09/08 GILEAD SCIENCES : First-Line Combination of Ambrisentan and Tadalafil Reduces Ri..
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
Gilead Sciences, Inc. : Income Statement Evolution
More Financials
Dynamic quotes